Poor medication adherence in clinical trials: consequences and solutions.
Poor adherence to medicines in clinical trials can undermine the value of the trials; for example, by compromising estimates of the benefits and risks of a medicine. In this article, we highlight such consequences and also discuss approaches to tackle this problem.
Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX, UK.
Alasdair
A
Breckenridge
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
Jeffrey K
JK
Aronson
Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.
Terrence F
TF
Blaschke
Global Health, Bill and Melinda Gates Foundation, Seattle 98102, USA.
Dan
D
Hartman
Department of Bioengineering and Therapeutic Sciences, University of California at San Francisco, California 94158, USA.
Carl C
CC
Peck
Westrock Healthcare, 4600 Vise, Belgium.
Bernard
B
Vrijens
D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D006801:Humans; D055118:Medication Adherence; D016896:Treatment Outcome